Trump’s Acting AG Puts Mail-Order Abortion Pills in DOJ’s Crosshairs

The fight over abortion access has shifted from courtrooms and clinics to the postal system, and Acting Attorney General Todd Blanche has now put the Justice Department at the center of an effort to choke off mail‑order abortion pills as a way to entrench post‑Dobbs abortion bans nationwide.

Key Points

Acting Attorney General Todd Blanche has pledged publicly and privately to end or severely restrict the mailing of abortion pills, especially mifepristone, and to devote Justice Department resources to that goal.
On a private call with faith leaders, Blanche linked “making Dobbs permanent in every single state” to stopping mail‑order abortion medications, signaling an ambition that reaches even into states where abortion remains legal.
Anti‑abortion groups and Republican senators are pressing DOJ to revive the 19th‑century Comstock Act and to back state lawsuits against the FDA’s liberalized mifepristone rules as the main legal levers for a nationwide clampdown.
Reproductive‑rights advocates, medical groups, and some legal scholars warn that a federal crackdown on mailed pills could function as a de facto national abortion ban, despite Dobbs leaving the issue formally to the states.

How Blanche Put Mail-Order Abortion Pills in DOJ’s Crosshairs

By the time Todd Blanche sat for his Senate confirmation hearings to become attorney general, the center of gravity in the abortion fight had already moved to medication abortion and the mail. More than half of abortions in the United States now occur using pills, most commonly mifepristone in combination with misoprostol, and a growing share is provided through telehealth and shipped to patients rather than dispensed in person. That model undermines the practical effect of state-level abortion bans: a person in a restrictive state can consult an out‑of‑state clinician and receive a package at her door. For Republican senators who opposed the Biden‑era loosening of FDA rules on mifepristone, Blanche’s confirmation hearings were a chance to demand a different federal posture.

Pressed repeatedly by senators including Katie Britt and John Cornyn, Blanche committed to taking federal action against the mailing of abortion pills. When Britt asked whether the Department of Justice would prioritize stopping abortion pills distributed by mail, Blanche answered, “Absolutely, senator,” and added that he believed the Biden administration’s approach to mifepristone had been “wrong.” In exchanges highlighted by conservative and anti‑abortion outlets, he described a “Wild West” of abortion pills being shipped into states that restrict abortion and promised to “commit our resources to stopping this.” These were not off‑hand remarks; they were carefully elicited pledges, on the record, in a setting where both the administration’s allies and opponents understood that the core question was whether DOJ would treat mail‑order pills as a national enforcement priority.

The Private Faith-Leader Call and the Promise to Make Dobbs “Permanent”

The most expansive articulation of Blanche’s plans did not emerge in the hearing room but on a private call with religious activists, later obtained and reported by national outlets. On a call hosted by the White House Faith Office and the group Intercessors for America, Blanche told faith leaders that the Justice Department was “working hand in hand” with the White House and federal health agencies “so that the Dobbs decision becomes permanent in every single state.” In that same call, he said the administration was “putting practices and policies in place” to stop shipment of abortion medications, making clear that in his view, curbing mail‑order pills was the operational route to locking in Dobbs nationwide.

For supporters on the call, this was cast as a long‑awaited answer to complaints that the Trump administration had moved too slowly against abortion pills. Anti‑abortion leaders had already organized letters and lobbying campaigns pressing President Trump’s team to act against what they described as an “abortion pill crisis” and “chemical abortion Wild West,” urging the administration to treat mailed pills as a direct challenge to state bans. Blanche’s assurances that “victory will be soon,” as one supportive summary described it, were a signal that DOJ would no longer remain on the sidelines of that fight but would become the lead vehicle for a coordinated federal crackdown.

The Legal Levers: FDA Regulation, State Lawsuits, and the Comstock Act

To understand what Blanche can actually do, you have to separate rhetoric from the legal instruments available. Three levers dominate the current strategy: FDA regulation of mifepristone, state‑led litigation over that regulation, and the dormant but still‑on‑the‑books Comstock Act of 1873.

First, FDA regulation. Under the Biden administration, the FDA loosened Risk Evaluation and Mitigation Strategy (REMS) rules on mifepristone, allowing telehealth prescribing and mail dispensing, and eliminating the requirement for in‑person pickup. Those changes are precisely what anti‑abortion groups want reversed. In one high‑profile lawsuit brought by Louisiana and other states, plaintiffs seek to force the FDA to reinstate stricter rules or withdraw approval for certain uses of the drug. The Trump administration’s Justice Department has, at times, defended FDA’s authority in court, but Blanche has been under intense pressure to change that posture. A coalition of more than 70 pro‑life organizations has urged him to stop asking judges to pause or dismiss states’ mifepristone suits and instead support the states’ efforts to roll back access. How Blanche directs DOJ to litigate those cases—defending FDA, staying neutral, or siding with state plaintiffs—will be a concrete test of his pledge.

Second, state lawsuits. Conservative attorneys general have used multi‑state suits to attack federal abortion policy before, and mifepristone is no exception. Analysts warn that if courts adopt the challengers’ theories and restrict the drug nationwide, the practical effect could be a far‑reaching cutback on abortion access even in states that protect it, because the most common method of early abortion would be curtailed everywhere. Pro‑life advocates see this as a feature; reproductive‑rights groups see it as an end‑run around Dobbs’ promise to return abortion to the states. Either way, DOJ’s stance under Blanche will influence how far and how fast those suits move.

The third and most contested lever is the Comstock Act, a 19th‑century anti‑vice law that, among other things, prohibits using the mail to send “every article or thing designed, adapted, or intended for producing abortion.” Although the Justice Department’s Office of Legal Counsel in 2022 concluded that Comstock does not bar mailing abortion drugs absent proof the sender intends an unlawful abortion, conservative lawyers and activists have argued that the plain text supports a far broader prohibition. Blanche has indicated he believes Comstock still has force as to abortion pills and has promised to “review” the 2022 opinion and the legality of mailing abortion drugs more generally. For anti‑abortion strategists, a DOJ willing to interpret Comstock aggressively could provide the backbone for federal prosecutions of prescribers, pharmacies, or distribution networks that ship pills into states with bans—and potentially more broadly.

What a Mail-Order Crackdown Would Look Like in Practice

There is a wide gap between a political pledge to end abortion pills by mail and the nuts and bolts of federal enforcement. The Justice Department does not regulate the practice of medicine, and most abortion‑related crime is prosecuted under state law. So what would it mean for Blanche to “commit resources” to stopping mailed pills?

One track is investigative and prosecutorial. Senators and activists have pressed Blanche to launch criminal investigations into networks that ship abortion pills into states where abortion is banned, particularly websites that connect U.S. patients with foreign pharmacies. In such a model, DOJ would use its traditional tools—grand juries, search warrants, coordination with postal inspectors and customs agents—to build cases where it can argue that pills were shipped with knowledge they would be used in violation of state bans, possibly under Comstock or related statutes. Another track involves supporting allied states: intervening in their lawsuits, filing statements of interest in their prosecutions, or providing federal investigative assistance targeting providers who mail pills into those jurisdictions.

At the same time, Blanche has signaled a desire to let the FDA’s ongoing safety review of mifepristone “do their work,” at least in the short term. In one hearing exchange, he suggested DOJ would not immediately move to re‑impose Trump‑era rules until the agency completed its review, even as he criticized the prior loosening of restrictions. That creates a two‑track timetable. The near‑term focus is likely to be on prosecuting what Blanche and his allies view as the most egregious “Wild West” actors—unregulated websites, overseas pill shipments—while the longer arc runs through FDA policy changes and major litigation that could restrict access more broadly.

The Stakes for States, Patients, and the Structure of Post-Dobbs Abortion Law

Blanche’s strategy fits a pattern that has emerged since Dobbs: national battles are being fought not over a formal nationwide abortion ban, which remains politically and legally difficult, but over federal levers that can reshape access everywhere without a single sweeping statute. Telehealth rules, postal regulations, FDA labeling decisions, shield laws that protect out‑of‑state providers, and now the Comstock Act have all become proxy battlefields. Mail‑order abortion pills sit at the intersection of all of these levers, which is why both sides see them as so consequential.

For states that protect abortion, a federal crackdown on mailed pills would be experienced as a direct intrusion. When Blanche told faith leaders he wanted Dobbs “permanent in every single state,” he was, in effect, promising to narrow the gap between states that ban abortion and those that protect it by attacking the channels—like the mail—that currently allow patients to reach across state lines. California and other blue states have already vowed to uphold mail‑order access to abortion drugs and to resist any attempt to enforce Comstock or similar federal restrictions against providers who serve out‑of‑state patients. That sets up potential conflicts between state shield laws and federal prosecutions, an area where the boundaries of federalism are not yet fully worked out.

For patients, especially in rural areas and in states with few or no clinics, mailed pills are not an abstract legal experiment but the most practical way to obtain early abortion care. Medical organizations and reproductive‑rights advocates argue that medication abortion has a strong safety record over decades of use and that restricting its availability by mail would disproportionately harm low‑income patients, those without reliable transportation, and those facing intimate partner violence who cannot safely travel. Some have described the emerging strategy around mifepristone as a “backdoor national abortion ban,” because eliminating the most common method of early abortion can sharply reduce access even where statutes technically permit it. Blanche’s pledge to make Dobbs “permanent” is heard in that light.

Competing Visions of DOJ’s Role and What Comes Next

Blanche’s comments have crystallized two starkly different visions of what the Justice Department should be in the post‑Dobbs landscape. Anti‑abortion groups, many of which backed President Trump’s second‑term bid on the expectation of further federal action, argue that DOJ has a duty to enforce Comstock, prosecute what they call illegal online pill networks, and side with states seeking to tighten FDA rules. They frame mailed abortion pills as a matter of consumer safety, rule of law, and the integrity of state bans: if pills can be shipped freely, they argue, democratic decisions in those states are being nullified in practice.

Reproductive‑rights advocates, democracy groups, and many legal scholars counter that Blanche’s commitments risk transforming DOJ from a neutral law‑enforcement agency into a vehicle for imposing a minority view on the whole country. They point to his private call with faith leaders and his embrace of a maximalist reading of Comstock as evidence that the administration is pursuing a national strategy that voters in many states do not support. Some warn that using an 1873 anti‑vice law as the foundation for 21st‑century abortion policy raises serious due‑process and separation‑of‑powers concerns. Members of the Senate Judiciary Committee who opposed Blanche’s confirmation have echoed these themes, arguing that he cannot credibly assure the public he will enforce the law even‑handedly while promising activists he will “roll back abortion access even in states that have laws protecting it.”

Those competing narratives will not be resolved by a single policy memo or lawsuit. Instead, they will play out through a series of highly specific decisions: whether DOJ reinterprets Comstock, how it litigates mifepristone cases, which enforcement targets it chooses, and how it responds when blue states shield their providers from prosecution. Each choice will either reinforce or narrow Blanche’s ambitious pledge to make Dobbs “permanent in every single state.” What is clear already is that by tying that pledge to the mail‑order abortion pill infrastructure, the Trump Justice Department has chosen its battlefield—and signaled that the next phase of America’s abortion conflict will be fought not only in state capitols and clinics, but in federal courthouses and postal distribution centers.

The post misrepresents the audio. Todd Blanche did not say he is working to “ban abortion in every single state.” In the recording (from a White House Faith Office call with religious leaders, later posted by Intercessors for America), Blanche stated that the Justice Department… https://t.co/17q1FKahmh

— Shawn Ferrebee 🇺🇸 (@FerrebeeShawn) August 5, 2026